Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 260

1.

Meniscal Ramp Lesion Repair Using an All-Inside Technique.

Negrín R, Reyes NO, Iñiguez M, Pellegrini JJ, Wainer M, Duboy J.

Arthrosc Tech. 2018 Feb 26;7(3):e265-e270. doi: 10.1016/j.eats.2017.09.001. eCollection 2018 Mar.

2.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
3.

Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation.

Muffly L, Sheehan K, Armstrong R, Jensen K, Tate K, Rezvani AR, Miklos D, Arai S, Shizuru J, Johnston L, Meyer E, Weng WK, Laport GG, Negrin RS, Strober S, Lowsky R.

Blood Adv. 2018 Mar 27;2(6):681-690. doi: 10.1182/bloodadvances.2017012104.

4.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

PMID:
29431743
5.

HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.

Spinner MA, Fernández-Viña M, Creary LE, Quinn O, Elder L, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Shizuru JA, Weng WK, Laport GG, Strober S, Lowsky R, Rezvani AR.

Blood Adv. 2017 Jul 25;1(17):1347-1357. doi: 10.1182/bloodadvances.2017007716. eCollection 2017 Jul 25.

6.

T cells expressing chimeric antigen receptor promote immune tolerance.

Pierini A, Iliopoulou BP, Peiris H, Pérez-Cruz M, Baker J, Hsu K, Gu X, Zheng PP, Erkers T, Tang SW, Strober W, Alvarez M, Ring A, Velardi A, Negrin RS, Kim SK, Meyer EH.

JCI Insight. 2017 Oct 19;2(20). pii: 92865. doi: 10.1172/jci.insight.92865. [Epub ahead of print]

7.

Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation.

Mavers M, Maas-Bauer K, Negrin RS.

Front Immunol. 2017 Jul 31;8:900. doi: 10.3389/fimmu.2017.00900. eCollection 2017. Review.

8.

Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.

Veeraputhiran M, Yang L, Sundaram V, Arai S, Lowsky R, Miklos D, Meyer E, Muffly L, Negrin R, Rezvani A, Shizuru J, Weng WK, Johnston L.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1744-1748. doi: 10.1016/j.bbmt.2017.06.005. Epub 2017 Jun 28.

9.

A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant.

Ronald JA, Kim BS, Gowrishankar G, Namavari M, Alam IS, D'Souza A, Nishikii H, Chuang HY, Ilovich O, Lin CF, Reeves R, Shuhendler A, Hoehne A, Chan CT, Baker J, Yaghoubi SS, VanBrocklin HF, Hawkins R, Franc BL, Jivan S, Slater JB, Verdin EF, Gao KT, Benjamin J, Negrin R, Gambhir SS.

Cancer Res. 2017 Jun 1;77(11):2893-2902. doi: 10.1158/0008-5472.CAN-16-2953.

10.

Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation.

Simonetta F, Alvarez M, Negrin RS.

Front Immunol. 2017 Apr 25;8:465. doi: 10.3389/fimmu.2017.00465. eCollection 2017. Review.

11.

Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis.

Pierini A, Nishikii H, Baker J, Kimura T, Kwon HS, Pan Y, Chen Y, Alvarez M, Strober W, Velardi A, Shizuru JA, Wu JY, Chiba S, Negrin RS.

Nat Commun. 2017 May 9;8:15068. doi: 10.1038/ncomms15068.

12.

Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells.

Du J, Paz K, Thangavelu G, Schneidawind D, Baker J, Flynn R, Duramad O, Feser C, Panoskaltsis-Mortari A, Negrin RS, Blazar BR.

Blood. 2017 Jun 8;129(23):3121-3125. doi: 10.1182/blood-2016-11-752444. Epub 2017 Apr 17.

13.

Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.

Chen YB, Efebera YA, Johnston L, Ball ED, Avigan D, Lekakis LJ, Bachier CR, Martin P, Duramad O, Ishii Y, Han S, Jung YJ, Lee D, Kunkel L, Negrin RS, Bui JD.

Biol Blood Marrow Transplant. 2017 Apr;23(4):625-634. doi: 10.1016/j.bbmt.2017.01.069. Epub 2017 Jan 16.

14.

Welcome to Blood Advances.

Negrin RS.

Blood Adv. 2016 Nov 22;1(1):1. doi: 10.1182/bloodadvances.2016001677. eCollection 2016 Nov 29. No abstract available.

15.

Introduction to a review series on chronic GVHD: from pathogenic B-cell receptor signaling to novel therapeutic targets.

Zeiser R, Negrin RS.

Blood. 2017 Jan 5;129(1):1-2. doi: 10.1182/blood-2016-10-735696. Epub 2016 Nov 7. No abstract available.

16.

Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning.

Müller AM, Florek M, Kohrt HE, Küpper NJ, Filatenkov A, Linderman JA, Hadeiba H, Negrin RS, Shizuru JA.

J Immunol. 2016 Nov 15;197(10):4151-4162. Epub 2016 Oct 10.

17.

DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease.

Nishikii H, Kim BS, Yokoyama Y, Chen Y, Baker J, Pierini A, Alvarez M, Mavers M, Maas-Bauer K, Pan Y, Chiba S, Negrin RS.

Blood. 2016 Dec 15;128(24):2846-2858. Epub 2016 Oct 19.

18.

Biomechanical and histological comparison between the cryopreserved and the lyophilized Gracilis tendon allograft for MPFL reconstruction, a cadaveric experimental study.

Negrín R, Duboy J, Olavarría F, Wainer M, Jimenez H, Las Heras F, Reyes N, Godoy H.

J Exp Orthop. 2016 Dec;3(1):20. doi: 10.1186/s40634-016-0056-2. Epub 2016 Sep 6.

19.

TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment.

Pierini A, Strober W, Moffett C, Baker J, Nishikii H, Alvarez M, Pan Y, Schneidawind D, Meyer E, Negrin RS.

Blood. 2016 Aug 11;128(6):866-71. doi: 10.1182/blood-2016-04-711275. Epub 2016 Jun 30.

20.

The NOTCH1/CD39 axis: a Treg trip-switch for GvHD.

Del Papa B, Pierini A, Sportoletti P, Baldoni S, Cecchini D, Rosati E, Dorillo E, Aureli P, Zei T, Iacucci Ostini R, Ruggeri L, Carotti A, Velardi A, Negrin R, Martelli MF, Falzetti F, Di Ianni M.

Leukemia. 2016 Sep;30(9):1931-4. doi: 10.1038/leu.2016.87. Epub 2016 Apr 29. No abstract available.

PMID:
27125307
21.

NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment.

Pierini A, Alvarez M, Negrin RS.

Stem Cells Int. 2016;2016:9025835. doi: 10.1155/2016/9025835. Epub 2016 Jan 5. Review.

22.

Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization.

Kuipers HF, Rieck M, Gurevich I, Nagy N, Butte MJ, Negrin RS, Wight TN, Steinman L, Bollyky PL.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1339-44. doi: 10.1073/pnas.1525086113. Epub 2016 Jan 19.

23.

Regulatory T Cell Immunotherapy in Immune-Mediated Diseases.

Pierini A, Schneidawind D, Nishikii H, Negrin RS.

Curr Stem Cell Rep. 2015 Dec 1;1(4):177-186. Epub 2015 Sep 12.

24.

Freeze and Thaw of CD4+CD25+Foxp3+ Regulatory T Cells Results in Loss of CD62L Expression and a Reduced Capacity to Protect against Graft-versus-Host Disease.

Florek M, Schneidawind D, Pierini A, Baker J, Armstrong R, Pan Y, Leveson-Gower D, Negrin R, Meyer E.

PLoS One. 2015 Dec 22;10(12):e0145763. doi: 10.1371/journal.pone.0145763. eCollection 2015.

25.

Graft-versus-host disease versus graft-versus-leukemia.

Negrin RS.

Hematology Am Soc Hematol Educ Program. 2015;2015:225-30. doi: 10.1182/asheducation-2015.1.225. Review.

PMID:
26637726
26.

Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.

Kurnellas MP, Ghosn EE, Schartner JM, Baker J, Rothbard JJ, Negrin RS, Herzenberg LA, Fathman CG, Steinman L, Rothbard JB.

Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15016-23. doi: 10.1073/pnas.1521206112. Epub 2015 Nov 30.

27.

MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.

Buechele C, Breese EH, Schneidawind D, Lin CH, Jeong J, Duque-Afonso J, Wong SH, Smith KS, Negrin RS, Porteus M, Cleary ML.

Blood. 2015 Oct 1;126(14):1683-94. doi: 10.1182/blood-2015-05-646398. Epub 2015 Aug 26.

28.

Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.

Nakasone H, Remberger M, Tian L, Brodin P, Sahaf B, Wu F, Mattsson J, Lowsky R, Negrin R, Miklos DB, Meyer E.

Haematologica. 2015 Nov;100(11):1477-85. doi: 10.3324/haematol.2015.125294. Epub 2015 Aug 6.

29.

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N.

Leukemia. 2015 Oct;29(10):2062-8. doi: 10.1038/leu.2015.212. Epub 2015 Jul 31.

30.

Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.

Rezvani AR, Kanate AS, Efron B, Chhabra S, Kohrt HE, Shizuru JA, Laport GG, Miklos DB, Benjamin JE, Johnston LJ, Arai S, Weng WK, Negrin RS, Strober S, Lowsky R.

Bone Marrow Transplant. 2015 Oct;50(10):1286-92. doi: 10.1038/bmt.2015.149. Epub 2015 Jul 6.

31.

Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.

Kim BS, Nishikii H, Baker J, Pierini A, Schneidawind D, Pan Y, Beilhack A, Park CG, Negrin RS.

Blood. 2015 Jul 23;126(4):546-57. doi: 10.1182/blood-2015-04-637587. Epub 2015 Jun 10.

32.

Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.

Pierini A, Colonna L, Alvarez M, Schneidawind D, Nishikii H, Baker J, Pan Y, Florek M, Kim BS, Negrin RS.

J Immunol. 2015 Jul 1;195(1):347-55. doi: 10.4049/jimmunol.1402861. Epub 2015 May 20.

33.

Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.

Percival MM, Medeiros BC, Tian L, Robeson S, Laport GG, Johnston LJ, Shizuru JA, Miklos DB, Arai S, Weng WK, Negrin RS, Lowsky R.

Bone Marrow Transplant. 2015 Jul;50(7):1004-1006. doi: 10.1038/bmt.2015.62. Epub 2015 Apr 20. No abstract available.

34.

Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.

Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, Shizuru JA, Negrin RN, Engleman EG, Strober S.

Clin Cancer Res. 2015 Aug 15;21(16):3727-39. doi: 10.1158/1078-0432.CCR-14-2824. Epub 2015 Apr 13.

35.

Engraftment of embryonic stem cells and differentiated progeny by host conditioning with total lymphoid irradiation and regulatory T cells.

Pan Y, Leveson-Gower DB, de Almeida PE, Pierini A, Baker J, Florek M, Nishikii H, Kim BS, Ke R, Wu JC, Negrin RS.

Cell Rep. 2015 Mar 24;10(11):1793-802.

36.

Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.

Schneidawind D, Baker J, Pierini A, Buechele C, Luong RH, Meyer EH, Negrin RS.

Blood. 2015 May 28;125(22):3491-500. doi: 10.1182/blood-2014-11-612762. Epub 2015 Mar 20.

37.

Unipotent Megakaryopoietic Pathway Bridging Hematopoietic Stem Cells and Mature Megakaryocytes.

Nishikii H, Kanazawa Y, Umemoto T, Goltsev Y, Matsuzaki Y, Matsushita K, Yamato M, Nolan GP, Negrin R, Chiba S.

Stem Cells. 2015 Jul;33(7):2196-207. doi: 10.1002/stem.1985. Epub 2015 Apr 27.

38.

ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation.

Logan AC, Wang Z, Alimoghaddam K, Wong RM, Lai T, Negrin RS, Grumet C, Logan BR, Zhang MJ, Spellman SR, Lee SJ, Miklos DB; Center for International Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2015 Apr;21(4):746-54. doi: 10.1016/j.bbmt.2014.12.036. Epub 2015 Jan 5.

39.

Identification of Orai1 channel inhibitors by using minimal functional domains to screen small molecule microarrays.

Sadaghiani AM, Lee SM, Odegaard JI, Leveson-Gower DB, McPherson OM, Novick P, Kim MR, Koehler AN, Negrin R, Dolmetsch RE, Park CY.

Chem Biol. 2014 Oct 23;21(10):1278-1292. doi: 10.1016/j.chembiol.2014.08.016. Epub 2014 Oct 9.

40.

CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.

Schneidawind D, Pierini A, Alvarez M, Pan Y, Baker J, Buechele C, Luong RH, Meyer EH, Negrin RS.

Blood. 2014 Nov 20;124(22):3320-8. doi: 10.1182/blood-2014-05-576017. Epub 2014 Oct 7.

41.

Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models.

Florek M, Sega EI, Leveson-Gower DB, Baker J, Müller AM, Schneidawind D, Meyer E, Negrin RS.

Blood. 2014 Sep 11;124(11):1832-42. doi: 10.1182/blood-2014-02-555128. Epub 2014 Jul 16.

42.

Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusion.

Filatenkov A, Baker J, Müller AM, Ahn GO, Kohrt H, Dutt S, Jensen K, Dejbakhsh-Jones S, Negrin RS, Shizuru JA, Engleman EG, Strober S.

Radiat Res. 2014 Aug;182(2):163-9. doi: 10.1667/RR13471.1. Epub 2014 Jul 3.

43.

Introduction to the review series on "Advances in hematopoietic cell transplantation".

Negrin RS.

Blood. 2014 Jul 17;124(3):307. doi: 10.1182/blood-2014-05-566679. Epub 2014 Jun 9. No abstract available.

44.

European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

Medeiros BC, Tian L, Robenson S, Laport GG, Johnston LJ, Shizuru JA, Miklos DB, Arai S, Benjamin JE, Weng WK, Negrin RS, Lowsky R.

Blood Cancer J. 2014 May 30;4:e216. doi: 10.1038/bcj.2014.35. No abstract available.

45.

Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance.

de Almeida PE, Meyer EH, Kooreman NG, Diecke S, Dey D, Sanchez-Freire V, Hu S, Ebert A, Odegaard J, Mordwinkin NM, Brouwer TP, Lo D, Montoro DT, Longaker MT, Negrin RS, Wu JC.

Nat Commun. 2014 May 30;5:3903. doi: 10.1038/ncomms4903.

46.

A killer choice for cancer immunotherapy.

Schmidt TL, Negrin RS, Contag CH.

Immunol Res. 2014 May;58(2-3):300-6. doi: 10.1007/s12026-014-8507-2. Review.

PMID:
24791943
47.

Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.

Benjamin J, Chhabra S, Kohrt HE, Lavori P, Laport GG, Arai S, Johnston L, Miklos DB, Shizuru JA, Weng WK, Negrin RS, Lowsky R.

Biol Blood Marrow Transplant. 2014 Jun;20(6):837-43. doi: 10.1016/j.bbmt.2014.02.023. Epub 2014 Mar 7.

48.

Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment.

Müller AM, Poyser J, Küpper NJ, Burnett C, Ko RM, Kohrt HE, Florek M, Zhang P, Negrin RS, Shizuru JA.

Blood. 2014 May 1;123(18):2882-92. doi: 10.1182/blood-2013-10-530212. Epub 2014 Mar 3.

49.

Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation.

Sega EI, Leveson-Gower DB, Florek M, Schneidawind D, Luong RH, Negrin RS.

PLoS One. 2014 Jan 27;9(1):e86551. doi: 10.1371/journal.pone.0086551. eCollection 2014.

50.

Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.

Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, Shaughnessy P, Snyder E, Bensinger W, Copelan E, Hosing C, Negrin R, Petersen FB, Rondelli D, Soiffer R, Leather H, Pazzalia A, Devine S.

Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308. doi: 10.1016/j.bbmt.2013.10.013. Epub 2013 Oct 17. Review.

Supplemental Content

Loading ...
Support Center